Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 7, 2017
Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell CollectionAmanda F Cashen, Michael Rettig, Feng Gao, et al.
Leukemia & Lymphoma|June 10, 2017
Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I studySagun Goyal, Eunhye Oak, Jingqin Luo, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 8, 2013
An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmaxEmmanuel Itti, Michel Meignan, Alina Berriolo-Riedinger, et al.
Blood Advances|June 7, 2019
Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantationNarendranath Epperla, Talha Badar, Aniko Szabo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 31, 2016
Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell TransplantIbraheem H Motabi, Armin Ghobadi, Jingxia Liu, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2024
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell LymphomasNicole Foley, Peter A Riedell, Nancy L Bartlett, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 7, 2014
Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphomaMyriam Sasanelli, Michel Meignan, Corinne Haioun, et al.
Blood|November 6, 2010
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemiaTodd A Fehniger, Geoffrey L Uy, Kathryn Trinkaus, et al.
Transplantation and Cellular Therapy|May 22, 2022
Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related MortalityLawrence Wayne Liu, Alicia Yn, Feng Gao, et al.
Leukemia & Lymphoma|April 29, 2016
A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndromeMathew A Cherian, Raoul Tibes, Feng Gao, et al.
Pageof 10